<Disease><Name>FABRY DISEASE</Name><Synonym>ANDERSON-FABRY DISEASE</Synonym><OMIM><Number>301500</Number><URL>http://omim.org/entry/301500</URL></OMIM><Orphanet><Number>324</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=324</URL></Orphanet><Protein><Number>Alpha-galactosidase A</Number><URL>http://www.uniprot.org/uniprot/P06280</URL></Protein><ExPASy><Number>3.2.1.22</Number><URL>http://enzyme.expasy.org/EC/3.2.1.22</URL></ExPASy><Gene>Xq22.1</Gene><ICD>E75.2</ICD><Summary>rare (1:55.000);X-linked recessive ;mutations in the GLA gene</Summary><Symptoms><symtomp><id>2347</id><symptom>anemia</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM | LABORATORY FINDINGS</category></symtomp><symtomp><id>2341</id><symptom>angiokeratoma</symptom><category>CARDIOVASCULAR SYSTEM | SKIN</category></symtomp><symtomp><id>2459</id><symptom>cardiac arrhythmia, dysrhythmia</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2104</id><symptom>cardiomyopathy</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3677</id><symptom>cardiomyopathy, hypertrophic</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2489</id><symptom>cerebral vascular disease</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2448</id><symptom>corneal clouding</symptom><category>EYES</category></symtomp><symtomp><id>2124</id><symptom>corneal deposits</symptom><category>EYES</category></symtomp><symtomp><id>2300</id><symptom>coronary heart disease</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3645</id><symptom>depression</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1982</id><symptom>diarrhea</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1883</id><symptom>ECG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1713</id><symptom>fever, severe or recurrent</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3431</id><symptom>hyperhidrosis</symptom><category>SKIN</category></symtomp><symtomp><id>2296</id><symptom>hypertension</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2431</id><symptom>hypohidrosis</symptom><category>SKIN</category></symtomp><symtomp><id>2488</id><symptom>myocardial infarction, myocardial ischemia</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1981</id><symptom>nausea</symptom><category>GASTROINTESTINAL SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1975</id><symptom>pain, abdominal / pain abdominal</symptom><category>BODY | GENERAL TOPICS</category></symtomp><symtomp><id>3778</id><symptom>pain, extremities (acroparesthesia)</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1938</id><symptom>paresthesia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3629</id><symptom>proteinuria</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>2461</id><symptom>renal failure, acute/chronic</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>4097</id><symptom>renal failure, chronic</symptom><category /></symtomp><symtomp><id>2263</id><symptom>strokelike episodes</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1935</id><symptom>vertigo, dizziness</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1980</id><symptom>vomiting</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp></Symptoms><Metabolites><metabolite><id>808</id><name>alpha-Galactosidase A</name><specimen>plasma</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1017</id><name>alpha-Galactosidase A</name><specimen>tears</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1018</id><name>alpha-Galactosidase A</name><specimen>leucocytes</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1019</id><name>Globotriaosylceramide</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>0.00</max><unit>mmol/mol creatinine</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1020</id><name>Globotriaosylceramide</name><specimen>plasma</specimen><value>increased</value><min>    </min><max>    </max><unit>no data</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1096</id><name>Protein</name><specimen>urine</specimen><value>increased</value><min>50.00</min><max>80.00</max><unit>mg/24 hr</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7380</id><title>Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients</title><author>Varela P,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>30</pages><co_aut>et al.</co_aut></literature><literature><id>7386</id><title>Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain</title><author>K&#246;rver S,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>28</pages><co_aut>et al.</co_aut></literature><literature><id>7394</id><title>Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study</title><author>Jahan S,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>10</pages><co_aut>et al.</co_aut></literature><literature><id>7918</id><title>Is the Alpha-Galactosidase A Variant p.Asp313Tyr (p.D313Y) Pathogenic for Fabry Disease? A systematic review</title><author>Effraimidis G,</author><journal>J Inherit Metab Dis</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7961</id><title>Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation</title><author>Azevedo O,</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>22</volume><number>0</number><pages>100566</pages><co_aut>et al.</co_aut></literature><literature><id>7009</id><title>[The Fabry nephropathy: new insight in diagnosis, monitoring and treatment]</title><author>Mignani R</author><journal>G Ital Nefrol</journal><year>2019</year><book /><volume>36</volume><number>4</number><pages /><co_aut /></literature><literature><id>6037</id><title>Mulberries in the urine: a tell-tale sign of Fabry disease</title><author>Chong PF,</author><journal>J Inherit Metab Dis</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Nakamura K, Kira R</co_aut></literature><literature><id>6043</id><title>Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study</title><author>Arends M,</author><journal>J Inherit Metab Dis</journal><year>2018</year><book /><volume>41</volume><number>1</number><pages>141-149</pages><co_aut>et al.</co_aut></literature><literature><id>6339</id><title>High incidence of co-existing factors significantly modifying the phenotype in patients with Fabry disease</title><author>Koca S,</author><journal>Gene</journal><year>2018</year><book /><volume>687</volume><number>0</number><pages>280-288</pages><co_aut>et al.</co_aut></literature><literature><id>7381</id><title>Fabry disease in the Spanish population: observational study with detection of 77 patients</title><author>Vieitez I,</author><journal>Orphanet J Rare Dis</journal><year>2018</year><book /><volume>13</volume><number>1</number><pages>52</pages><co_aut>et al.</co_aut></literature><literature><id>4444</id><title>Fabry Disease</title><author>Bokhari SR,</author><journal>StatPearls [Internet]</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Al Aboud A</co_aut></literature><literature><id>4445</id><title>Fabry disease: A fundamental genetic modifier of cardiac function</title><author>Tadevosyan A</author><journal>Curr Res Transl Med</journal><year>2017</year><book /><volume>65</volume><number>1</number><pages>10-14</pages><co_aut /></literature><literature><id>4452</id><title>[The Fabrys Disease Cardiomyopathy as Differential Diagnosis of Acute Coronary Syndrome]</title><author>Oder D,</author><journal>Dtsch Med Wochenschr</journal><year>2017</year><book /><volume>142</volume><number>6</number><pages>442-449</pages><co_aut>et al.</co_aut></literature><literature><id>4453</id><title>Fabry Disease</title><author>Mehta A,</author><journal>GeneReviews&#174; [Internet]</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Hughes DA</co_aut></literature><literature><id>5311</id><title>Contribution of inflammatory pathways to Fabry disease pathogenesis</title><author>Rozenfeld P,</author><journal>Mol Genet Metab</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Feriozzi S</co_aut></literature><literature><id>5312</id><title>A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease</title><author>Talbot A,</author><journal>Mol Genet Metab</journal><year>2017</year><book /><volume>122</volume><number>1</number><pages>121-125</pages><co_aut>et al.</co_aut></literature><literature><id>6038</id><title>Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease</title><author>Shimohata H,</author><journal>CEN Case Rep</journal><year>2017</year><book /><volume>6</volume><number>2</number><pages>148-151</pages><co_aut>et al.</co_aut></literature><literature><id>4446</id><title>Is it Fabry disease?</title><author>Schiffmann R,</author><journal>Genet Med</journal><year>2016</year><book /><volume>18</volume><number>12</number><pages>1181-1185</pages><co_aut>et al.</co_aut></literature><literature><id>4447</id><title>The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations</title><author>Citro V,</author><journal>Int J Mol Sci</journal><year>2016</year><book /><volume>17</volume><number>0</number><pages>12</pages><co_aut>et al.</co_aut></literature><literature><id>4448</id><title>Fabry Disease: A Disorder of Childhood Onset</title><author>Schiffmann R,</author><journal>Pediatr Neurol</journal><year>2016</year><book /><volume>64</volume><number>0</number><pages>10-20</pages><co_aut>Ries M</co_aut></literature><literature><id>4449</id><title>Enzyme replacement therapy for Anderson-Fabry disease</title><author>El Dib R,</author><journal>Cochrane Database Syst Rev</journal><year>2016</year><book /><volume>70</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>4450</id><title>Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features</title><author>Ranieri M,</author><journal>Curr Treat Options Neurol</journal><year>2016</year><book /><volume>18</volume><number>7</number><pages>33</pages><co_aut>et al.</co_aut></literature><literature><id>4451</id><title>Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis</title><author>Zar-Kessler C,</author><journal>Therap Adv Gastroenterol</journal><year>2016</year><book /><volume>9</volume><number>4</number><pages>626-634</pages><co_aut>et al.</co_aut></literature><literature><id>6039</id><title>A Renal Variant of Fabry Disease Diagnosed by the Presence of Urinary Mulberry Cells</title><author>Shimohata H,</author><journal>Intern Med</journal><year>2016</year><book /><volume>55</volume><number>23</number><pages>3475-3478</pages><co_aut>et al.</co_aut></literature><literature><id>2717</id><title>Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry</title><author>Eng CM</author><journal>J Inher Met Dis</journal><year>2007</year><book /><volume>30</volume><number>0</number><pages>184-192</pages><co_aut>et al.</co_aut></literature><literature><id>2616</id><title>Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease</title><author>Bierer G</author><journal>J Inher Met Dis</journal><year>2006</year><book /><volume>29</volume><number>0</number><pages>572-579</pages><co_aut>et al.</co_aut></literature><literature><id>2623</id><title>The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease</title><author>Kalliokoski RJ</author><journal>J Inher Met Dis</journal><year>2006</year><book /><volume>29</volume><number>0</number><pages>112-118</pages><co_aut>et al.</co_aut></literature><literature><id>2639</id><title>Paroxysmal vertigo as the presenting symptom of Fabry disease</title><author>Pruss H</author><journal>Neurology</journal><year>2006</year><book /><volume>66</volume><number>2</number><pages>249</pages><co_aut>Bohner G, Zschenderlein R</co_aut></literature><literature><id>2640</id><title>Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey&lt;</title><author>Lidove O</author><journal>Int J Clin Pract</journal><year>2006</year><book /><volume>60</volume><number>9</number><pages>1053-1059</pages><co_aut>et al.</co_aut></literature><literature><id>2641</id><title>Enzyme replacement therapy and renal function in 201 patients with Fabry disease</title><author>Schwarting A</author><journal>Clin Nephrol</journal><year>2006</year><book /><volume>66</volume><number>0</number><pages>77-84</pages><co_aut>et al.</co_aut></literature><literature><id>2671</id><title>Heterogenic biochemical, metabolic and genetic features of Fabry disease</title><author>Shin YS</author><journal>J Inher Met Dis Suppl 1</journal><year>2006</year><book /><volume>29</volume><number>0</number><pages>22</pages><co_aut>Korall H, Breinig B, Podskarbi T</co_aut></literature><literature><id>2377</id><title>Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study</title><author>Eto Y</author><journal>J Inherit Metab Dis</journal><year>2005</year><book /><volume>28</volume><number>4</number><pages>575-583</pages><co_aut>et al.</co_aut></literature><literature><id>2378</id><title>Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spe</title><author>Kitagawa T</author><journal>Mol Genet Metab</journal><year>2005</year><book /><volume>85</volume><number>3</number><pages>196-202</pages><co_aut>et al.</co_aut></literature><literature><id>1799</id><title>Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy</title><author>Meikle PJ</author><journal>Pediatrics</journal><year>2004</year><book /><volume>114</volume><number>4</number><pages>909-916</pages><co_aut>et al.</co_aut></literature><literature><id>1088</id><title>Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector</title><author>Ohsugi K</author><journal>J Hum Genet</journal><year>2000</year><book /><volume>45</volume><number>0</number><pages>1-5</pages><co_aut>et al.</co_aut></literature><literature><id>1089</id><title>Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease</title><author>Schiffmann R</author><journal>Proc Natl Acad Sci U S A</journal><year>2000</year><book /><volume>97</volume><number>0</number><pages>365-370</pages><co_aut>et al.</co_aut></literature><literature><id>1090</id><title>Cardiac variant of Fabrys disease mimicking hypertrophic cardiomyopathy</title><author>Chimenti C</author><journal>Cardiologia</journal><year>1999</year><book /><volume>44</volume><number>0</number><pages>469-473</pages><co_aut>et al.</co_aut></literature><literature><id>59</id><title>alpha-Galactosidase A deficiency: Fabry disease</title><author>Desnick RJ</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>0</number><pages>2741-2784</pages><co_aut>Ioannou YA, Eng CM</co_aut></literature><literature><id>653</id><title>Successful treatment of painful crises of Fabry disease with low dose morphine</title><author>Gordon KE</author><journal>Pediatr Neurol</journal><year>1995</year><book /><volume>12</volume><number>0</number><pages>250-251</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>